Clinical Trials
9 trialsNCT03598998 2026-05-26
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT03035331 2026-05-04
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT03240211 2026-04-07
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
University of Virginia
Phase 1 Active not recruiting
NCT04752826 2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2 Recruiting
NCT03210662 2026-01-13
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03278782 2026-01-09
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05313243 2025-03-20
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Yale University
Phase 2 Recruiting
NCT04795869 2023-10-10
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Northwestern University
Phase 2 Withdrawn
NCT03021057 2019-04-17
Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas
The University of Hong Kong
Phase 2 Unknown